Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Motesanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 18/20 | 0.98 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.98 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.98 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.98 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | RAF1 | P04049 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
| ▸ | FYN | P06241 | 1/20 | 0.98 |
| ▸ | CSF1R | P07333 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Motesanib SCHEMBL29354461 | 0.99 | KDR (1.00) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL187470 | 0.99 | KDR (1.00) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29361754 | 0.96 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL29353301 | 0.96 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| Motesanib SCHEMBL446673 | 0.96 | KDR (0.95) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3150119 | 0.91 | KDR (0.85) | KDRRETMAP3K20RIPK3CIT | |
| Hydrochloric Acid SCHEMBL448288 | 0.89 | KDR (0.78) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL4537062 | 0.89 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL3144781 | 0.89 | KDR (0.81) | KDRRETMAP3K20RIPK3CIT | |
| SCHEMBL444347 | 0.88 | KDR (0.79) | KDRRETMAP3K20RIPK3CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311808-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | KDR 13/4885RET 2801/4885PDGFRB 131/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | KDR 8/4885RET 2733/4885PDGFRB 66/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | KDR 15/4885RET 2278/4885PDGFRB 115/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | KDR 8/4885RET 2733/4885PDGFRB 66/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | KDR 13/4885RET 2801/4885PDGFRB 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.